vs
Amphastar Pharmaceuticals, Inc.（AMPH）とWestrock Coffee Co（WEST）の財務データ比較。上の社名をクリックして会社を切り替えられます
Westrock Coffee Coの直近四半期売上が大きい（$339.5M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.9倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -6.6%、差は20.0%）。Westrock Coffee Coの前年同期比売上増加率が高い（48.3% vs -1.8%）。Westrock Coffee Coの直近四半期フリーキャッシュフローが多い（$27.8M vs $24.6M）。過去8四半期でWestrock Coffee Coの売上複合成長率が高い（32.8% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
ウェストロックコーヒー社は、コーヒー、紅茶、機能性飲料の総合ソリューションを提供するグローバル企業です。原料調達、焙煎、製造、流通を一貫して行い、北米をはじめ世界各国の小売店、外食産業、法人顧客に対し、カスタマイズされた製品やサービスを提供しています。
AMPH vs WEST — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $339.5M |
| 純利益 | $24.4M | $-22.6M |
| 粗利率 | 46.8% | 11.5% |
| 営業利益率 | 19.4% | -2.6% |
| 純利益率 | 13.3% | -6.6% |
| 売上前年比 | -1.8% | 48.3% |
| 純利益前年比 | -35.7% | 8.3% |
| EPS（希薄化後） | $0.51 | $-0.22 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $339.5M | ||
| Q3 25 | $191.8M | $354.8M | ||
| Q2 25 | $174.4M | $280.9M | ||
| Q1 25 | $170.5M | $213.8M | ||
| Q4 24 | $186.5M | $229.0M | ||
| Q3 24 | $191.2M | $220.9M | ||
| Q2 24 | $182.4M | $208.4M | ||
| Q1 24 | $171.8M | $192.5M |
| Q4 25 | $24.4M | $-22.6M | ||
| Q3 25 | $17.4M | $-19.1M | ||
| Q2 25 | $31.0M | $-21.6M | ||
| Q1 25 | $25.3M | $-27.2M | ||
| Q4 24 | $38.0M | $-24.6M | ||
| Q3 24 | $40.4M | $-14.3M | ||
| Q2 24 | $37.9M | $-17.8M | ||
| Q1 24 | $43.2M | $-23.7M |
| Q4 25 | 46.8% | 11.5% | ||
| Q3 25 | 51.4% | 11.7% | ||
| Q2 25 | 49.6% | 14.7% | ||
| Q1 25 | 50.0% | 13.6% | ||
| Q4 24 | 46.5% | 16.6% | ||
| Q3 24 | 53.3% | 16.8% | ||
| Q2 24 | 52.2% | 19.9% | ||
| Q1 24 | 52.4% | 19.4% |
| Q4 25 | 19.4% | -2.6% | ||
| Q3 25 | 13.2% | -2.4% | ||
| Q2 25 | 24.2% | -5.3% | ||
| Q1 25 | 21.9% | -6.1% | ||
| Q4 24 | 24.2% | -4.3% | ||
| Q3 24 | 29.8% | -5.8% | ||
| Q2 24 | 30.3% | -7.9% | ||
| Q1 24 | 27.9% | -5.3% |
| Q4 25 | 13.3% | -6.6% | ||
| Q3 25 | 9.0% | -5.4% | ||
| Q2 25 | 17.8% | -7.7% | ||
| Q1 25 | 14.8% | -12.7% | ||
| Q4 24 | 20.4% | -10.7% | ||
| Q3 24 | 21.1% | -6.5% | ||
| Q2 24 | 20.8% | -8.5% | ||
| Q1 24 | 25.1% | -12.3% |
| Q4 25 | $0.51 | $-0.22 | ||
| Q3 25 | $0.37 | $-0.20 | ||
| Q2 25 | $0.64 | $-0.23 | ||
| Q1 25 | $0.51 | $-0.29 | ||
| Q4 24 | $0.74 | $-0.26 | ||
| Q3 24 | $0.78 | $-0.16 | ||
| Q2 24 | $0.73 | $-0.20 | ||
| Q1 24 | $0.81 | $-0.27 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $49.9M |
| 総負債低いほど良い | $608.7M | $444.1M |
| 株主資本純資産 | $788.8M | $-1.9M |
| 総資産 | $1.6B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $49.9M | ||
| Q3 25 | $276.2M | $34.0M | ||
| Q2 25 | $231.8M | $44.0M | ||
| Q1 25 | $236.9M | $33.1M | ||
| Q4 24 | $221.6M | $26.2M | ||
| Q3 24 | $250.5M | $22.4M | ||
| Q2 24 | $217.8M | $24.3M | ||
| Q1 24 | $289.6M | $12.6M |
| Q4 25 | $608.7M | $444.1M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $393.1M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-1.9M | ||
| Q3 25 | $776.7M | $11.4M | ||
| Q2 25 | $757.5M | $18.2M | ||
| Q1 25 | $751.3M | $71.4M | ||
| Q4 24 | $732.3M | $97.5M | ||
| Q3 24 | $727.7M | $110.3M | ||
| Q2 24 | $713.3M | $81.5M | ||
| Q1 24 | $672.4M | $91.7M |
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $983.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 4.03× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $36.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $27.8M |
| FCFマージンFCF / 売上 | 13.4% | 8.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-107.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $36.7M | ||
| Q3 25 | $52.6M | $-26.6M | ||
| Q2 25 | $35.6M | $-7.0M | ||
| Q1 25 | $35.1M | $-22.1M | ||
| Q4 24 | $29.0M | $2.8M | ||
| Q3 24 | $60.0M | $-332.0K | ||
| Q2 24 | $69.1M | $-23.7M | ||
| Q1 24 | $55.3M | $8.0M |
| Q4 25 | $24.6M | $27.8M | ||
| Q3 25 | $47.2M | $-44.7M | ||
| Q2 25 | $25.0M | $-27.5M | ||
| Q1 25 | $24.4M | $-63.4M | ||
| Q4 24 | $16.6M | $-15.4M | ||
| Q3 24 | $46.2M | $-36.7M | ||
| Q2 24 | $63.1M | $-59.9M | ||
| Q1 24 | $46.5M | $-60.9M |
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 24.6% | -12.6% | ||
| Q2 25 | 14.3% | -9.8% | ||
| Q1 25 | 14.3% | -29.7% | ||
| Q4 24 | 8.9% | -6.7% | ||
| Q3 24 | 24.1% | -16.6% | ||
| Q2 24 | 34.6% | -28.7% | ||
| Q1 24 | 27.1% | -31.7% |
| Q4 25 | 4.5% | 2.6% | ||
| Q3 25 | 2.8% | 5.1% | ||
| Q2 25 | 6.1% | 7.3% | ||
| Q1 25 | 6.3% | 19.3% | ||
| Q4 24 | 6.7% | 7.9% | ||
| Q3 24 | 7.2% | 16.5% | ||
| Q2 24 | 3.3% | 17.4% | ||
| Q1 24 | 5.1% | 35.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
